You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


BenevolentAI doses participants in BEN-8744 study

BenevolentAI, a company focusing on artificial intelligence (AI) that boosts biopharma discovery, has revealed that the initial group of participants have been dosed across a phase 1 clinical trial of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744.